Generic drug company Actavis announced Monday plans to buy Warner Chilcott for $8.5 billion in an all-stock buyout leading to a rise in shares for both companies. According to a press release offered by Actavis, the deal will lead to a new conglomerate generating $11 billion in annual revenue. According to the generic drug company, the move is part of its agenda to strengthen its specialty pharmaceutical operations. Actavis made a $5.9 billion buyout of Watson Pharmaceuticals last October, launching the company onto the global stage.
Featured News
Fifth Circuit Upholds Dismissal of Antitrust Suit Against NAR
Sep 10, 2026 by
CPI
Saudi Wealth Fund Weighs Merger of EA and Savvy Games
Sep 10, 2026 by
CPI
South Korea Antitrust Regulator Pushes Back on Korean Air Bid to Ease Merger Curbs
Sep 10, 2026 by
CPI
China’s Top Court Steps Up Antitrust Enforcement Push
Sep 10, 2026 by
CPI
US Justice Department Examines Nvidia’s $17 Billion Groq Deal
Sep 10, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 27, 2026 by
CPI
CPI Talks… with Jonathan Skrmetti, Attorney General of Tennessee
Aug 27, 2026 by
Jonathan Skrmetti
What the Live Nation Jury Instructions Tell Us About California’s Unfair Competition Law
Aug 27, 2026 by
Henry Hauser, Brent Nakamura, Ashley Kaplan, Brian Wang & Cari Jeffries
From Backroom Deals to Public Scrutiny: The Tunney Act’s Past, Present, and Future
Aug 27, 2026 by
Christina M. Black & Ashley A. Locke
Understanding the Fragility of Economic Concentration Through the Principles of Ecology
Aug 27, 2026 by
Alexandra Spring